Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at BofA Merrill from Buy to Neutral. $99 price target. Macro uncertainty, deal risks offset fundamental strength.
Arthur J. Gallagher
upgraded at Brean from Hold to Buy. $35 price target. Company should see better rate momentum.
upgraded at Goldman to Buy. $21 price target. Street estimates may not be too conservative.
upgraded at Morgan Stanley to Overweight. Stock is attractive, following a 24% decline since early June. $88 price target.
upgraded at BofA Merrill from Underperform to Neutral. $42 price target. Solid guidance and strong risk/reward profile.
upgraded at Jefferies from Neutral to Buy. $25 price target. Valuation call as EPS expectations are low and sentiment negative.
downgraded at Deutsche Bank from Buy to Hold. $75 price target. Lack of significant near term catalysts.
upgraded at BofA Merrill from Neutral to Buy. $42 price target. Potash market set to strengthen, major catalysts at hand.
downgraded at Citigroup from Buy to Hold. $27 price target. Weaker than expected results and long term growth remains cloudy.
downgraded at UBS from Buy to Neutral. $38 price target. Lower visibility and revised outlook not clearly "beatable."
downgraded at Credit Suisse from Neutral to Underperform. $34 price target. Rising risk and uncertainty in the federal funding environment.
downgraded at Baird to Neutral. Valuation call, based on a $59 price target.
downgraded at Baird to Neutral from Outperform, Robert Baird said. $72 price target. Company is seeing lower oncology orders.
Varian Medical numbers lowered at Goldman. Shares of VAR now seen reaching $57, according to Goldman Sachs. Estimates also cut, as the company is realizing slower growth. Sell rating.
End of report.
This article was written by a staff member of TheStreet.